CDNA CareDx, Inc.

Nasdaq caredx.com


$ 15.59 $ -0.39 (-2.45 %)    

Wednesday, 05-Nov-2025 09:43:19 EST
QQQ $ 617.99 $ -0.50 (-0.08 %)
DIA $ 470.82 $ 0.04 (0.01 %)
SPY $ 674.52 $ -0.46 (-0.07 %)
TLT $ 89.42 $ -0.08 (-0.09 %)
GLD $ 365.98 $ -0.46 (-0.13 %)
$ 14.52
$ 15.95
$ 15.47 x 200
$ 15.69 x 100
$ 15.46 - $ 16.45
$ 10.96 - $ 26.37
1,493,513
na
746.8M
$ 1.50
$ 10.60
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-04-2025 09-30-2025 10-Q
2 08-06-2025 06-30-2025 10-Q
3 04-30-2025 03-31-2025 10-Q
4 02-27-2025 12-31-2024 10-K
5 11-04-2024 09-30-2024 10-Q
6 07-31-2024 06-30-2024 10-Q
7 05-09-2024 03-31-2024 10-Q
8 02-28-2024 12-31-2023 10-K
9 11-08-2023 09-30-2023 10-Q
10 08-08-2023 06-30-2023 10-Q
11 05-10-2023 03-31-2023 10-Q
12 02-27-2023 12-31-2022 10-K
13 11-03-2022 09-30-2022 10-Q
14 08-04-2022 06-30-2022 10-Q
15 05-05-2022 03-31-2022 10-Q
16 02-24-2022 12-31-2021 10-K
17 10-28-2021 09-30-2021 10-Q
18 07-29-2021 06-30-2021 10-Q
19 05-05-2021 03-31-2021 10-Q
20 02-24-2021 12-31-2020 10-K
21 10-29-2020 09-30-2020 10-Q
22 08-04-2020 06-30-2020 10-Q
23 04-30-2020 03-31-2020 10-Q
24 02-28-2020 12-31-2019 10-K
25 10-31-2019 09-30-2019 10-Q
26 08-01-2019 06-30-2019 10-Q
27 05-08-2019 03-31-2019 10-Q
28 03-06-2019 12-31-2018 10-K
29 11-08-2018 09-30-2018 10-Q
30 08-09-2018 06-30-2018 10-Q
31 05-10-2018 03-31-2018 10-Q
32 03-22-2018 12-31-2017 10-K
33 11-09-2017 09-30-2017 10-Q
34 08-11-2017 06-30-2017 10-Q
35 06-09-2017 03-31-2017 10-Q
36 04-21-2017 12-31-2016 10-K
37 11-15-2016 09-30-2016 10-Q
38 08-22-2016 06-30-2016 10-Q
39 05-16-2016 03-31-2016 10-Q
40 03-29-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 caredx-raises-fy2025-sales-guidance-from-367000m-373000m-to-372000m-376000m-vs-368883m-est

CareDx (NASDAQ:CDNA) raises FY2025 sales outlook from $367.000 million-$373.000 million to $372.000 million-$376.000 million vs...

 caredx-q3-adj-eps-028-beats-014-estimate-sales-100055m-beat-95251m-estimate

CareDx (NASDAQ:CDNA) reported quarterly earnings of $0.28 per share which beat the analyst consensus estimate of $0.14 by 97.18...

 caredx-announces-publication-of-the-second-study-from-surveillance-heartcare-outcomes-registry-in-the-journal-of-the-american-college-of-cardiology-second-shore-study-validates-allosure-heart-an-integral-component-of-heartcare-as-a-reliable-biomarker-for-antibody-mediated-rejection-in-heart-transplant-recipients

a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated,...

 caredx-to-feature-new-ivd-products-and-ivdr-certification-for-alloseq-tx-and-qtype-at-ashi-2025-annual-meeting

Furthers Global Leadership in Donor Organ and Transplant Recipient HLA TypingCareDx, Inc. (NASDAQ:CDNA) – The Transplant Compan...

 btig-reiterates-buy-on-caredx-maintains-22-price-target

BTIG analyst Mark Massaro reiterates CareDx (NASDAQ:CDNA) with a Buy and maintains $22 price target.

 btig-reiterates-buy-on-caredx-maintains-22-price-target

BTIG analyst Mark Massaro reiterates CareDx (NASDAQ:CDNA) with a Buy and maintains $22 price target.

 caredx-urges-noridian-to-preserve-coverage-for-combination-and-personalized-molecular-testing-opposes-surveillance-limits-and-bundled-payments-in-draft-lcd-dl40060

CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, developme...

 caredx-battles-reimbursement-uncertainty-as-market-overlooks-long-term-potential

CareDx, Inc. faces uncertainty with proposed reimbursement changes, but has long-term potential in the $8 billion transplant so...

 william-blair-initiates-coverage-on-caredx-with-market-perform-rating

William Blair analyst Andrew Brackmann initiates coverage on CareDx (NASDAQ:CDNA) with a Market Perform rating.

 wells-fargo-maintains-equal-weight-on-caredx-lowers-price-target-to-14

Wells Fargo analyst Brandon Couillard maintains CareDx (NASDAQ:CDNA) with a Equal-Weight and lowers the price target from $1...

 caredx-names-nathan-smith-as-cfo
CareDx Names Nathan Smith As CFO
08/06/2025 21:10:25

 caredx-narrows-fy2025-sales-guidance-from-365000m-375000m-to-367000m-373000m-vs-370794m-est

CareDx (NASDAQ:CDNA) narrows FY2025 sales outlook from $365.000 million-$375.000 million to $367.000 million-$373.000 million v...

 caredx-q2-adj-eps-010-misses-012-estimate-sales-86679m-miss-90563m-estimate

CareDx (NASDAQ:CDNA) reported quarterly earnings of $0.10 per share which missed the analyst consensus estimate of $0.12 by 18....

 caredx-publishes-koar-study-in-american-journal-of-transplantation-showcasing-allosure-dd-cfdna-for-enhanced-kidney-rejection-detection-and-biopsy-guidance

KOAR, the Largest Prospective Study of Its Kind, Demonstrates Clinical Utility of AlloSure® in Kidney Transplant SurveillanceAl...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION